GetLatka · Apr 2025
Estimates annual revenue around $900K, reports roughly 6 employees, and lists Adil Yusuf as CEO in its compiled company data.
AI-designed Protein Therapeutics
Public company, workplace, funding, and market signals
AI-native biotech designing custom affinity reagents and other protein tools for research teams and diagnostic developers, using AI/protein design plus wet-lab validation to deliver results in weeks rather than months.
Primary product
Custom affinity reagents
Founded
2021
Headquarters
San Francisco, California, United States
Team size
1-10
Industry
Biotechnology Research
Sub-industry
AI protein design / affinity reagents
Offices
0 jobs at Medium Biosciences
Check back later for new openings
Business model
Stage
Seed / early-stage VC
Total raised
$125K
Latest round
Accelerator/Incubator · Sep 2021
Latest amount
$125K
Investors
Small founder-led team with an interdisciplinary AI/protein-design focus, rapid project scoping, and an experimental-validation-oriented product process.
Pricing
Custom, project-based engagement; consultation and project scoping are publicly offered as free, then work is scoped per target/application.
Differentiators
Technology
Customers
Competitors
Estimated revenue
under $1M
GetLatka · Apr 2025
Estimates annual revenue around $900K, reports roughly 6 employees, and lists Adil Yusuf as CEO in its compiled company data.
Tracxn · Dec 2024
Profiles the company’s seed funding history and names Y Combinator as the lead investor in its latest visible round.
TechCrunch · Sep 2021
Early public coverage of Medium Biosciences as a YC Summer 2021 company; described the company as using machine learning to find new enzymes for biotech companies.
PitchBook
Shows multiple deal entries, including an accelerator/incubator round and later early-stage VC deal entries, and lists named investors including AIX Ventures, E14 Fund, Village Global, and SBXi.